Even considering this limitation, the results of this study clearly indicate that the use of an osteoimmunological biomarker like the RANKL/OPG ratio could provide a significant improvement in the clinical evaluation of the COVID-19 effect on bone loss. This evidence concerns the gene TNFSF11 and COVID-19.